Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

396

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Type 2 Diabetes
Interventions
DRUG

MBX-102

MBX-102 200 mg once daily for 16 weeks

DRUG

MBX-102

MBX-102 400 mg once daily for 16 weeks

DRUG

MBX-102

MBX-102 600 mg once daily for 16 weeks

DRUG

Placebo

MBX-102 Placebo once daily for 16 weeks

DRUG

Actos

Actos 30 mg once daily for 16 weeks

Trial Locations (67)

13091

Department of Endocrinology, Ziv Medical Center, Safed

22100

Institution of Diabetes and Metabolism, Nahariya

23249

McGuire VA Medical Center, Richmond

23294

National Clinical Research, Richmond

29651

Radiant Research - Greer, Greer

31996

Rambam Medical Center, Haifa

33026

Andres Patron DO PA, Pembroke Pines

33156

International Research Associates, LLC, Miami

34684

Suncoast Clinical Research, Inc., Palm Harbor

34780

Linn Medical Center, Haifa

38654

Olive Branch Research, Olive Branch

43235

Optimed Research, LLC, Columbus

58100

Wolfson Medical Center, Holon

60031

Clinical Investigation Specialists, Inc., Gurnee

60607

Cedar-Crosse Research Center, Chicago

64353

Zamenhoff Medical Center, Tel Aviv

72401

NEA Clinic, Jonesboro

75230

Dallas Diabetes & Endocrine Center, Dallas

77081

Mercury Pharma Services, Houston

78229

Diabetes & Glandular Disease Research Associates, P.A., San Antonio

79705

Diabetes Center of the Southwest, Midland

84101

Soroka Medical Center, Beersheba

90017

The Intermed Group, Los Angeles

90033

LAC/USC Medical Center, Los Angeles

90620

Associated Pharmaceutical Research Center, Inc., Buena Park

91120

Hadassah University Hospital, Jerusalem

93106

Clalit Health Services, Jerusalem

411011

Diabetes Care and Research Center, Maharashtra

500082

Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad

560034

St. John's Medical College Hospital, Bangalore

560054

M.S. Ramaih Medical College & Hospital, Bangalore

575001

Kasturba Medical College Hospital, Attavar

576104

Kasturba Hospital, Manipal

632004

Christian Medical College Hospital, Vellore

682026

Amrita Institute of Medical Sciences, Kochi

B1708IFF

Consultorio Integral de Atencion al Diabetico (CIAD), Buenos Aires

B1824KAJ

CIMEL, Buenos Aires

B6740CWC

Centro de Atencion Integral en Diabetes, Endocrinologica y Metabolismo, Buenos Aires

C1121ABE

Fundacion CIDEA, Buenos Aires

C1405CNF

Sanatorio Municipal Dr. Julio Mendez, Buenos Aires

C1405CWB

Instituto Medico Especializado, Buenos Aires

CP1650

Hospital Thompson, Buenos Aires

Unknown

Clinica Dleta Zarate, Buenos Aires

Hospital Privado de Comunidad, Buenos Aires

Consultorios Asociados de Endocrinologia, Capital Federal

Fundacion Marcelino Rusculleda Batlle, Córdoba

CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan Capital

Bharti Research Institute of Diabetes & Endocrinology, Karnāl

Sterling Hospital, Ahmedabad

Diacon Hospital, Bangalore

Dr. V. Seshiah Diabetes Care & Research Institute, Chennai

Apollo Gleneages/Dept. of Endocrinology, Kolkata

Chowpatty Medical Center, Mumbai

Mediheights Healthcare Pvt. Ltd., Mumbai

Kerala Institute of Medical Sciences, Trivandrum

Endocrinology Institute, Haemek Medical Center, Afula

Barzilai Medical Center, Ashkelon

Endocrinology & Diabetes Institute, Petah Tikva

Institute of Metabolic Diseases, Tel Aviv

Assaf Haroffe Medical Center, Zrifin

X5000BNB

Instituto Latinoamericano de Investigaciones Clinicas, Córdoba

X5000IKK

Sanatorio Parque, Córdoba

M5519XAC

Instituto de Clinica Medica y Diabetes, Mendoza

R8324BSS

Policlio Modelo de Cipoletti, Rio Negro

A4406CLA

Hospital San Bernardo, Salta

600 116

Sri Ramachandra Medical Centre, Chennai

411 011

KEM Hospital, Pune

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00353587 - Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin | Biotech Hunter | Biotech Hunter